Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet

Avner Fink, Eric Hung, Indranil Singh, Yinon Ben-Neriah*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Acute myeloid leukemia (AML) is a highly aggressive disease with high relapse and mortality rates. Recent years have shown a surge in novel therapeutic development for AML, both in clinical and preclinical stages. These developments include targeted therapies based on AML-specific molecular signatures as well as more general immune modulation and vaccination studies. In this review, we will explore the evolving arena of AML therapy and suggest some intriguing connections between immune system modulation and targeted therapy. Improved understanding of the immune system involvement in various stages of the disease and the crosstalk between immune effectors, targeted therapy, and AML cells can provide a better framework for designing the next generation of AML therapies.

Original languageAmerican English
Pages (from-to)34-43
Number of pages10
JournalEuropean Journal of Immunology
Volume52
Issue number1
DOIs
StatePublished - Jan 2022

Bibliographical note

Funding Information:
Research work in the authors' laboratory are supported by the Israel Science Foundation (ISF)?Centers of Excellence, ISF Grant 3165/19 within the Israel Precision Medicine Program, the Joseph Lebovic charitable Foundation, the European Research Council (883552-ONCODESTROYER), and the Israel Cancer Research Fund Professorship.

Funding Information:
Research work in the authors' laboratory are supported by the Israel Science Foundation (ISF)—Centers of Excellence, ISF Grant 3165/19 within the Israel Precision Medicine Program, the Joseph Lebovic charitable Foundation, the European Research Council (883552‐ONCODESTROYER), and the Israel Cancer Research Fund Professorship.

Publisher Copyright:
© 2021 Wiley-VCH GmbH

Keywords

  • Humans
  • Leukemia, Myeloid, Acute/genetics
  • Molecular Targeted Therapy

Fingerprint

Dive into the research topics of 'Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet'. Together they form a unique fingerprint.

Cite this